NCT02021435Unknown不适用
Using Salt Substitute to Reduce Population Blood Pressure in Tibet: Tibet Salt Reduction Study
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 4,500
- 试验地点
- 2
- 主要终点
- Difference in change from baseline in blood pressure between intervention and control
研究概览
简要总结
- Research background
- High blood pressure is one of the most important risk factors to cardiovascular diseases (CVDs). Reducing population blood pressure can control CVD incidence and lower mortality effectively. Much research has proven that adjusting for Na and K intake level can reduce blood pressure. According to the China Salt Substitute Study, the systolic blood pressure of intervention group which used salt substitute is 5.4 mmHg lower than that of control group. Life expectancy in Tibet is 67 years old. It is estimated that the use of salt substitute among population in Tibet can reduce total mortality in Tibet by 20%. China Salt Substitute Study in Tibet (CSSS-Tibet), found that salt substitute is effective in lowering both systolic and diastolic blood pressure and offers a simple, low-cost approach for hypertension control among Tibetans in China (unpublished results). However, the study focused on hypertensive patients, the effectiveness of hypertension control by providing free salt substitute to the entire population remains unknown, and a large-scale trial is needed.
- Objectives
- Primary objective is to observe the effect of providing salt substitute on population blood pressure in Tibet. Secondary objective is to observe the effect of such intervention on population mortality, cardiovascular mortality and life expectancy. In addition, the data collected from high-risk population (sub-group) in the study will be used in China Salt Substitute and Stroke Study (SSaSS). Also, serum cholesterol and random blood glucose of people over 60 in Tibet will be collected.
- Method
- The study is a open, cluster-randomized, controlled trial.
- 30 villages with 15 to 35 households each and a distance of at least five kilometers in between will be selected from Damxung county and Maizhokunggar county. The two counties have an average altitude of over 4000 meters in Tibet Autonomous Region.
- All selected villages will be randomly assigned to intervention group or control group on a 1:1 ratio.
- All household in the selected villages will be recruited if they meet the eligibility criteria. Approximately 4,500 participants will be enrolled
- Intervention group receives free salt substitute. Control group will continue to buy their own normal salt. Both group will receive the same health education on salt reduction.
- Outcome - Primary outcome is blood pressure. Secondary outcomes include total mortality, cardiovascular disease mortality, life expectancy, serum cholesterol level of people over 60, and random blood glucose level of people over 60.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All family households in the selected satellite village will be invited to participate in the study
- •Family households will be excluded from participating if they meet one or more of the following exclusion criteria:
- •Any member in the family is using a potassium-sparing diuretic
- •Any member in the family is using a potassium supplement
- •Any member in the family has serious renal impairment
- •Any member in the family over 18 could not sign informed consent
- •Life expectancy of any member in the family is shorter than 6 months in doctor's opinion
排除标准
- 未提供
结局指标
主要结局
Difference in change from baseline in blood pressure between intervention and control
时间窗: Baseline, 6,12, 24 months
次要结局
- Difference in total mortality between intervention and control(6, 12, 24 months)
- Difference in cardiovascular disease mortality between intervention and control(6,12, 24 months)
- Difference in life expectancy between intervention and control group(6, 12, 24 months)
- The distribution of blood glucose level in population over 60 years old(baseline)
- Distribution of serum cholesterol level in population over 60 years old(baseline)
研究者
Xingshan Zhao
Vice-president; Director, Department of Cardiology
Beijing Jishuitan Hospital
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Improving Blood Pressure Control Through the myBPmyLife mHealth ApplicationHypertensionNCT05154929University of Michigan608
已完成
不适用
Salt reduction intervention: a cluster randomized trial in northern ThailandCadiovascular diseaseCirculatory SystemCardiovascular disease, unspecifiedISRCTN39416277Ministry of Education, Culture, Sports, Science and Technology (Japan)753
已完成
2 期
Blood Pressure Lowering in Dialysis (BOLD) TrialBlood PressureEnd Stage Renal Disease on Dialysis (Diagnosis)Chronic Kidney DiseasesChronic Kidney Disease Stage 5NCT03459807University of California, San Francisco50
已完成
不适用
China Salt Substitute StudyCardiovascular DiseasesHypertensionNCT00145756The George Institute600
已完成
4 期
Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATINGenetics HypertensionHypertensionNCT03683069Brigham and Women's Hospital90